For people with type 2 diabetes, GLP-1 drugs like semaglutide and dulaglutide lower the chance of having a stroke caused by a blood clot by nearly 1 in 6 — more than any other diabetes medicine.

1

Pro

0

Against

Evidence from Studies

Supporting (1)

1

Community contributions welcome

1

Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs

Narrative Review

Human

2024 Aug 9

This study says that GLP-1 drugs help protect the heart and blood vessels in diabetics by reducing dangerous plaque buildup, which lowers the chance of strokes caused by blocked arteries — exactly what the claim says.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs

Score: 1

DOI: 10.3390/jcm13164674

Similar Assertions

GLP-1 diabetes drugs help prevent heart attacks and strokes mainly by lowering blood sugar and helping people lose weight—not by lowering blood pressure or bad cholesterol.

48

0

82%

Losing just 1 kilogram (about 2.2 pounds) of body weight while taking GLP-1 diabetes drugs is linked to a 7% lower chance of having a heart attack, stroke, or dying from heart disease.

48

0

80%

GLP-1 receptor agonists reduce cardiovascular event rates independently of LDL cholesterol modulation, primarily through weight loss and improved metabolic health.

48

0

78%

For people with type 2 diabetes, lowering their blood sugar by 1% using certain diabetes medications is linked to a 25% lower chance of having a heart attack, stroke, or dying from heart disease.

48

0

77%

GLP-1 diabetes drugs that lower blood sugar and weight the most tend to offer the biggest protection against heart attacks and strokes in people with type 2 diabetes.

48

0

77%